UNLOCKING tRNA’S FULL THERAPEUTIC POTENTIAL
TURNING tRNA’S SOPHISTICATED BIOLOGY INTO PROGRAMMABLE MEDICINES WITH POWERFUL THERAPEUTIC PROPERTIES.
tRNA sequences and chemical modifications are key to their structure, function, and stability. There exist more than 1034 tRNA sequences with more than 120 natural and synthetic modifications possible for each nucleotide, yielding the potential to generate more engineered, modified tRNA oligonucleotides than atoms in the universe.
Design
RESTORE
DELIVER
EXPAND
ALLTRNA’S PROGRAMmABLE
tRNA PLATFORM
Alltrna's platform uniquely combines internal expertise and proprietary machine learning tools to comb through the vast combinatorial landscape of possible tRNA molecules to engineer tRNA oligonucleotides with desired pharmacologic properties and unlock tRNA’s full therapeutic power.
A PLATFORM FOR UNLOCKING BEST-IN-CLASS tRNA MEDICINES
Alltrna has validated the potential of its platform to design, modify, synthesize, and deliver chemically modified, engineered tRNA oligonucleotides with significantly increased potency and activity. This includes demonstration of in vivo readthrough of premature termination codons (PTCs) to restore the production of full-length proteins, independent of gene and mutation location.
THE FIRST OF MANY APPLICATIONS: A UNIFYING THERAPEUTIC APPROACH FOR NONSENSE MUTATIONS
Across all genetic diseases, rare and common, about ten percent of patients have a nonsense mutation that halts protein production early, causing their disease. These patients, representing approximately 30 million people, can be classified as having Stop Codon Disease.
